Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

Abstract: The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.

Abstract: A motor vehicle (1) has a supporting structure (3) that includes an A-pillar (5), and has a protective apparatus (8) that includes an inflatable airbag that can be inflated from a rest state into a deployed state by way of activation. The inflatable airbag is accommodated exclusively in the A-pillar (5) in the rest state.

Abstract: A fluid-operated braking system (1) for a tractor-trailer vehicle includes a trailer control valve (2), a parking brake module (3), and an electronic control unit (4) electrically connected to the trailer control valve (2) and to the parking brake module (3). A pressure fluid accumulator (13) of the braking system (1) is connected to a control pressure input (P43) of the trailer control valve (2). A redundancy circuit controls the control pressure input (P43), even during a malfunction of the control unit (4). The parking brake module (3) includes a control valve (14), a redundancy valve (15) and a changeover valve (16) controlled by an electronic switch unit (20) with a holding function. When the control unit (4) malfunctions, the last error-free switching position of the control valve (14) or the redundancy valve is maintained until a operationally safe resting state is reached or the ignition system is switched off.

Abstract: An insertion-type connecting arrangement having at least one first and one second insertion-type connector and an arrangement of insertion points having at least one first and one second insertion point for the insertion of the insertion-type connectors, there being connected to the first insertion-type connector two or more cores laid up at a preset first lay length and to the second insertion-type connector two or more cores laid up at a preset second lay length, having a coding mechanism which allows the first insertion-type connector to be inserted in the first insertion point but not in the second one and which allows the second insertion-type connector to be inserted in the second insertion point but not in the first one.

Abstract: A method for analyzing a component is provided. The method includes the steps of: (iii) providing the electrophoretic or thermophoretic movement of the component into a second fluid flow; (iv) diverting a part of a first fluid flow, a part of the second fluid flow, or parts of the first fluid flow and the second fluid flow, wherein the diverted part is a third fluid flow which includes, the component; (v) contacting the third fluid flow with a fourth fluid flow, such as to form a laminar flow; (vi) providing the diffusion of the component into the fourth fluid flows.

Abstract: A pedestal for loading a sample into a microfluidic device is provided. The pedestal comprising, a surface for receiving the sample and positioning it above a port; and a side support configured to provide a liquid barrier by the action of surface tension.

Abstract: A fluid flow controller for introducing fluids into a microfluidic device is provided. The fluid flow controller comprising, at least one high resistance fluid pathway provided between an inlet port and a connection port; at least one low resistance fluid pathway between the inlet and connection port; and at least one valve configured to enable fluid flow through the high resistance fluid pathway, the low resistance fluid pathway or both.

Abstract: A single-layer valve is provided. The valve comprises a microfluidic pathway at least partially defined by a flexible membrane which is configured to deform when subjected to an actuation torque, and a discontinuity bounded by a first surface. The length of the discontinuity is constant across the full width of the first surface. The valve is configured such that the actuation torque on the membrane is larger in a first direction than a second direction substantially opposite to the first direction.

Abstract: A system and method for modeling cross system content between a hub and one or more backend systems is disclosed. Model content of one or more data models is stored in a model stack defined in a storage. The model content of each data model includes model metadata representing a model of a backend system. Cross model content is stored in a cross model stack. The cross model content includes reference metadata representing one or more references associated with a data model of one backend system and that reference a data model of another backend system. Central cross model content is stored in a central cross model stack. The central cross model content includes one or more cross elements that do not belong to the model content of any of the data models, and that establish a connection between two data models of different backend systems.

Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.

Abstract: A control system for a motor vehicle is based on environmental sensors of the motor vehicle and on a database. The environmental sensors are arranged and configured to capture an environment of the motor vehicle continuously and to provide environmental data of the motor vehicle. A position sensor is arranged and configured to detect a position of the motor vehicle continuously and to provide position data of the motor vehicle. A speed sensor is arranged and configured to detect a speed of the motor vehicle continuously and to provide speed data of the motor vehicle. A timer is configured to determine respectively current time information. A database is configured to store transmitted data sets and to provide stored data sets. An interface is arranged and configured to transmit traffic information to a driving instance of the motor vehicle.

Abstract: A fluidic system is provided. The system comprises: a rigid housing (12), a plurality of flexible reagent containers (14) contained within the housing (12); wherein each reagent container (14) has a connection port (16) through which a reagent can flow, in use, on the application of pressure. The system further comprises a single pressure source (18) configured to apply pressure to the interior of the rigid housing (12); a microfluidic device configured to analyse one or more fluids provided from the plurality of reagent containers; and a plurality of channels (20) configured to transfer fluid from the plurality of reagent containers (14) to the microfluidic device. The ratio of resistances provided by a combination of the connection ports and the plurality of channels dictates the ratio of flow rates of the reagents. The claimed system allows for an accurate control of the various reagent flow rates while minimizing fluctuations in the relative flow rates.

Abstract: A vehicle tailgate structure including a first panel portion including a composite material and a second panel portion overmolded onto the first panel portion, the first and second panel portions forming together a body portion, a transverse beam and side beams connecting the transverse beam to the body portion, wherein the transverse beam includes a hinge attachment portion configured to receive a hinge attachment part, wherein the first panel portion has a bent strip in the transverse beam, and wherein the bent strip is raised with respect to a remaining portion of the first panel portion.

Abstract: A static devolatilization apparatus (1) for germ reduction of a fluid is disclosed. The apparatus (1) comprises a housing (10), an inlet (12), an outlet (14), a fluid-contacting surface (20) comprising a biocide (22) embodied to reduce the germ count of the fluid (2), wherein the fluid-contacting surface (20) is a fluid-contacting surface (20) of a static mixing element (30). The present invention further relates to a process for reducing the germ count of a fluid containing germs (2?) using the apparatus (1) and also to the use of the apparatus (1) in the germ reduction of fuel oil, of food products, or water decontamination, preferably decontamination of waste water, industrial process water, or the treatment of drinking water.

Abstract: Methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R1 is halo; R2 is halo; and Q is CH or N.

Abstract: The present invention relates to a drive arrangement, comprising a motor drive shaft, which makes the drive force of a motor available, an output shaft, via which the drive arrangement outputs and accumulates a rotational force, a coupling, which is designed to transmit a rotational force from the motor drive shaft to the output shaft and from the output shaft to the motor drive shaft, and a braking arrangement, which counteracts a rotational movement of the output shaft with a braking force.